Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized linezolid dosing in neurosurgical patients with Gram-positive bacterial infection
ChiCTR2500095252Phase 4Completed
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of linezolid in Gram-positive bacterial infection (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Plasma concentration, Cerebrospinal fluid concentration and 16 more. Started Jan 2025; status: completed.
02
Drugs
linezolid
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on ChiCTR2500095252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095252.